Followers | 372 |
Posts | 20770 |
Boards Moderated | 4 |
Alias Born | 04/08/2011 |
Friday, May 19, 2017 9:37:58 AM
OTC Disclosure & News Service
-
Lexaria raises US$1M from Warrant Exercise
KELOWNA, BC--(Marketwired - May 19, 2017) - Lexaria Bioscience Corp (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces it has received US$970,230.05 from the exercise of warrants previously granted. The stock warrants, which otherwise expired on May 15 2017, were exercised at the price of US$0.2273, for a total of 4,268,500 common shares being issued. All warrants are being exercised by third parties who are neither officers nor directors of the Company.
"Lexaria's balance sheet is now the strongest it has ever been," commented Chris Bunka, CEO. "We have raised over US$3 million in the past six months, which fully funds the Company's business plans until 2019. We are now focussed on developing our patent portfolio and continuing our work with prospective licensees and resellers."
Following issuance of these common shares, Lexaria will have 66,506,009 common shares issued and outstanding. No commissions or placement fees have been paid related to the funds received from this warrant exercise. Proceeds will be used for general corporate purposes. Lexaria extends its thanks to its loyal shareholders for their continued support.
The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
About Lexaria
Lexaria Bioscience Corp is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company's lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also improving taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company's technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
www.lexariabioscience.com
Damn it feels good to be a gangster.
Recent LEXX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 02:55:35 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/06/2024 08:11:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 04:25:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 03:32:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 03:12:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2024 08:12:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/12/2024 05:26:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/06/2024 11:00:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 07:28:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:30:59 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/16/2024 08:47:26 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 05:00:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 06:51:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 07:12:07 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 01/24/2024 06:33:08 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/18/2024 07:38:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/12/2024 10:11:16 PM
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream • GlobeNewswire Inc. • 01/11/2024 01:30:00 PM
- Beyond Diabetes, a Blockbuster Horizon Beckons • InvestorsHub NewsWire • 01/10/2024 01:45:00 PM
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform • GlobeNewswire Inc. • 01/09/2024 01:30:00 PM
- Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs • InvestorsHub NewsWire • 01/08/2024 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 10:07:45 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM